BiotechTube

Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV Infection

Conditions

HIV Infection, HIV

Trial Timeline

Mar 1, 2026 → Jan 1, 2028

NCT ID
NCT07209267

About Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg

Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mg is a phase 2 stage product being developed by Eli Lilly for HIV Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07209267. Target conditions include HIV Infection, HIV.

What happened to similar drugs?

20 of 20 similar drugs in HIV Infection were approved

Approved (20) Terminated (3) Active (0)
✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
✅Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅Lopinavir/RitonavirAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07209267Phase 2Recruiting

Competing Products

20 competing products in HIV Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1944ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1195.1ModernaPhase 1
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 3
0
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
BSG005Alkem LaboratoriesPhase 1/2
39
Zotatifin + PlaceboeFFECTOR TherapeuticsPhase 1
19
AAVLP-HPV + Placebo2A PharmaPhase 1
19
CT-P59CelltrionPhase 1
29
CT-P63 + PlaceboCelltrionPhase 1
29